Literature DB >> 10737123

Novel mutations of mitochondrial complex I in pathologically proven Parkinson disease.

S Kösel1, E M Grasbon-Frodl, U Mautsch, R Egensperger, U von Eitzen, D Frishman, S Hofmann, K D Gerbitz, P Mehraein, M B Graeber.   

Abstract

Complete sequence analysis of all mitochondrial complex I genes was performed in 22 cases of neuropathologically confirmed idiopathic Parkinson disease (PD). DNA from the substantia nigra was used as a template for polymerase chain reaction-based genomic sequencing. Seven novel mutations causing the exchange of amino acids were detected in subunit genes ND1 (3992 C/ T, 4024 A/G), ND4 (11253 T/C, 12084 C/T), ND5 (13711 G/A, 13768 T/C), and ND6 (14582 T/C). In addition, five known missense mutations affecting the ND1 (3335 T/C, 3338 T/C), ND2 (5460 G/A), ND3 (10398 A/G), and ND5 (13966 A/G) genes as well as three secondary LHON mutations (4216 T/C, 4917 A/ G, 13708 G/A) were found in the PD group. Among the novel mutations, the 11253 T/C transition which changes a conserved isoleucine residue into threonine is most likely to be of functional relevance. Furthermore, 43 synonymous polymorphisms were detected in PD brains, including 20 novel sequence variants. Haplogroup analysis revealed that most unique missense mutations were found in PD cases belonging to the D(c) haplogroup. Our data are in line with the view that PD is not a single disease entity but comprises a genetically heterogeneous group of disorders. The results of our study further suggest that 90% or more of all idiopathic PD cases are not due to sequence variation of mitochondrial complex I, but that mitochondrial mutations may play a pathogenic role in a subset of PD patients.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10737123     DOI: 10.1007/s100480050029

Source DB:  PubMed          Journal:  Neurogenetics        ISSN: 1364-6745            Impact factor:   2.660


  17 in total

1.  Sequence analysis of two nuclear encoded subunits (10 and 51 kDa) of mitochondrial complex I in Parkinson disease.

Authors:  Eva M Grasbon-Frodl; P Mehraein
Journal:  Neurogenetics       Date:  2002-03       Impact factor: 2.660

Review 2.  The unresolved role of mitochondrial DNA in Parkinson's disease: An overview of published studies, their limitations, and future prospects.

Authors:  Amica C Müller-Nedebock; Rebecca R Brennan; Marianne Venter; Ilse S Pienaar; Francois H van der Westhuizen; Joanna L Elson; Owen A Ross; Soraya Bardien
Journal:  Neurochem Int       Date:  2019-06-21       Impact factor: 3.921

3.  Association of mitochondrial DNA 10398 polymorphism in invasive breast cancer in malay population of peninsular malaysia.

Authors:  Nadiah Tengku Baharudin; Hasnan Jaafar; Zafarina Zainuddin
Journal:  Malays J Med Sci       Date:  2012-01

4.  Transcriptome analysis reveals link between proteasomal and mitochondrial pathways in Parkinson's disease.

Authors:  D C Duke; L B Moran; M E Kalaitzakis; M Deprez; D T Dexter; R K B Pearce; M B Graeber
Journal:  Neurogenetics       Date:  2006-05-13       Impact factor: 2.660

Review 5.  Does mitochondrial DNA play a role in Parkinson's disease? A review of cybrid and other supportive evidence.

Authors:  Russell H Swerdlow
Journal:  Antioxid Redox Signal       Date:  2011-05-25       Impact factor: 8.401

Review 6.  The two-century journey of Parkinson disease research.

Authors:  Serge Przedborski
Journal:  Nat Rev Neurosci       Date:  2017-03-17       Impact factor: 34.870

7.  Direct regulation of complex I by mitochondrial MEF2D is disrupted in a mouse model of Parkinson disease and in human patients.

Authors:  Hua She; Qian Yang; Kennie Shepherd; Yoland Smith; Gary Miller; Claudia Testa; Zixu Mao
Journal:  J Clin Invest       Date:  2011-03       Impact factor: 14.808

8.  Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease.

Authors:  Todd L Edwards; William K Scott; Cherylyn Almonte; Amber Burt; Eric H Powell; Gary W Beecham; Liyong Wang; Stephan Züchner; Ioanna Konidari; Gaofeng Wang; Carlos Singer; Fatta Nahab; Burton Scott; Jeffrey M Stajich; Margaret Pericak-Vance; Jonathan Haines; Jeffery M Vance; Eden R Martin
Journal:  Ann Hum Genet       Date:  2010-01-08       Impact factor: 1.670

9.  MEF2D Mediates the Neuroprotective Effect of Methylene Blue Against Glutamate-Induced Oxidative Damage in HT22 Hippocampal Cells.

Authors:  Zi-Wei Chen; Anmin Liu; Qingyu Liu; Jingkao Chen; Wen-Ming Li; Xiao-Juan Chao; Qian Yang; Pei-Qing Liu; Zi-Xu Mao; Rong-Biao Pi
Journal:  Mol Neurobiol       Date:  2016-03-03       Impact factor: 5.590

Review 10.  Initiation of neuronal damage by complex I deficiency and oxidative stress in Parkinson's disease.

Authors:  Laszlo Tretter; Ildiko Sipos; Vera Adam-Vizi
Journal:  Neurochem Res       Date:  2004-03       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.